Heterogeneous implantable devices for drug delivery
The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.
1. An implantable device for delivery of a pharmaceutical substance to a patient, comprising:
a rod-shaped core comprising a core polymeric material, wherein the core does not comprise a pharmaceutical substance, wherein the core polymeric material is ethylene vinyl acetate (EVA), and wherein the core has a diameter of about 0.5 mm to about 3.5 mm;
a first layer comprising a first-layer pharmaceutical substance and EVA surrounding the core; and
one or more additional layers, wherein each of the one or more additional layers comprise an independently selected additional pharmaceutical substance and EVA in a blend,
wherein the EVA has a flexural strength when unblended with pharmaceutical substance,
wherein the blend of the additional pharmaceutical substance and the EVA in each of the one or more additional layers has about 20% to 90% of the flexural strength of the EVA unblended with pharmaceutical substance;
wherein the first-layer pharmaceutical substance and the additional pharmaceutical substances are the same or different;
wherein at least one of the first-layer pharmaceutical substance and the additional pharmaceutical substances is L-triiodothyronine;
wherein the first-layer pharmaceutical substance and the additional pharmaceutical substances are released through pores that open to the surface of the device; and
wherein the outermost layer of the device comprises at least one of the additional pharmaceutical substances.
2. The device of claim 1 , wherein the first-layer pharmaceutical substance is L-triiodothyronine.
3. The device of claim 1 , wherein the first-layer pharmaceutical substance and the one or more additional pharmaceutical substances in the one or more additional layers are independently selected from the group consisting of L-triiodothyronine and L-thyroxine.
4. The device of claim 1 , wherein each of the first layer and the one or more additional layers has a different average concentration of pharmaceutical substance.
5. The device of claim 4 , wherein the average concentration of pharmaceutical substance in the one or more additional layers decreases with increasing distance from the core.
6. The device of claim 4 , wherein the average concentration of pharmaceutical substance in the one or more additional layers increases with increasing distance from the core.
7. The device of claim 1 , wherein the first-layer pharmaceutical substance is L-triiodothyronine.
8. The device of claim 7 , wherein the first layer comprises about 10% to 85% L-triiodothyronine.
9. The device of claim 1 , wherein the first-layer pharmaceutical substance and each of the one or more additional pharmaceutical substances are L-triiodothyronine.
10. A method for delivering a first-layer pharmaceutical substance and one or more additional pharmaceutical substances to a patient in need thereof, comprising the step of inserting a device of claim 1 subcutaneously into the patient.
11. The method of claim 10 , wherein the device remains implanted in the patient for about 3 months to about 24 months.
12. The method of claim 11 , wherein the concentration of pharmaceutical substance in the blood is approximately constant or essentially constant for about 3 months to about 24 months.